Taipei Exchange - Delayed Quote TWD

Lukas Biomedical Inc. (6814.TWO)

Compare
27.60
0.00
(0.00%)
As of 9:00:11 AM GMT+8. Market Open.
Currency in TWD All numbers in thousands
Download
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
211,844.00
184,787.00
157,618.00
181,410.00
Cost of Revenue
93,290.00
86,881.00
61,555.00
62,962.00
Gross Profit
118,554.00
97,906.00
96,063.00
118,448.00
Operating Expense
153,953.00
146,475.00
140,313.00
125,109.00
Operating Income
-35,399.00
-48,569.00
-44,250.00
-6,661.00
Net Non Operating Interest Income Expense
-2,850.00
-2,847.00
-4,372.00
-4,792.00
Pretax Income
-37,896.00
-49,919.00
-47,832.00
-9,956.00
Tax Provision
151.00
151.00
1,662.00
586.00
Net Income Common Stockholders
-38,047.00
-50,070.00
-49,494.00
-10,542.00
Diluted NI Available to Com Stockholders
-38,047.00
-50,070.00
-49,494.00
-10,542.00
Basic EPS
-1.02
-1.35
-1.50
-0.32
Diluted EPS
-1.02
-1.35
-1.50
-0.32
Basic Average Shares
37,105.51
37,005.38
33,079.94
33,079.94
Diluted Average Shares
37,105.51
37,005.38
33,079.94
33,079.94
Total Expenses
247,243.00
233,356.00
201,868.00
188,071.00
Net Income from Continuing & Discontinued Operation
-38,047.00
-50,070.00
-49,494.00
-10,542.00
Normalized Income
-38,021.40
-50,152.40
-50,443.60
-11,627.60
Interest Income
103.00
73.00
43.00
40.00
Interest Expense
2,953.00
2,920.00
4,415.00
4,832.00
Net Interest Income
-2,850.00
-2,847.00
-4,372.00
-4,792.00
EBIT
-34,943.00
-46,999.00
-43,417.00
-5,124.00
EBITDA
-3,956.00
-10,932.00
-361.00
43,280.00
Reconciled Cost of Revenue
93,290.00
86,881.00
61,555.00
62,962.00
Reconciled Depreciation
30,987.00
36,067.00
43,056.00
48,404.00
Net Income from Continuing Operation Net Minority Interest
-38,047.00
-50,070.00
-49,494.00
-10,542.00
Total Unusual Items Excluding Goodwill
-32.00
103.00
1,187.00
1,357.00
Total Unusual Items
-32.00
103.00
1,187.00
1,357.00
Normalized EBITDA
-3,924.00
-11,035.00
-1,548.00
41,923.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-6.40
20.60
237.40
271.40
12/31/2020 - 12/31/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4197.TWO Visgeneer Inc.
9.78
0.00%
 
6999.TWO Han Biomedical
36.00
+3.75%
 
6709.TWO Advagene Biopharma Co., Ltd.
20.20
0.00%
 
6827.TWO MegaPro Biomedical Co., Ltd
14.45
+2.48%
 
6748.TWO ACRO Biomedical Co., Ltd.
24.75
+0.83%
 
7776.TWO Anya
38.60
+7.67%
 
4170.TWO VBI
13.80
-1.43%
 
6610.TWO TWi Biotechnology, Inc.
13.75
+0.73%
 
6744.TWO Feng Chi Biotech Corp.
19.70
0.00%
 
7754.TWO AnnJi
32.70
-3.25%